CFTR ΔF508 carrier status, risk of breast cancer before the age of 40 and histological grading in a population-based case-control study

International Journal of Cancer

Volumn 79, Issue 5, 1998, Pages 487-489

  Southey, Melissa C ^a,b   Batten, Leigh ^a   Andersen, Chris R ^a   Mccredie, Margaret R E ^c   Giles, Graham G ^d   Dite, Gillian ^b   Hopper, John L ^b   Venter, Deon J ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d CANCER EPIDEMIOLOGY CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR; ADENOSINE TRIPHOSPHATE; BRCA2 PROTEIN; CFTR PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; GENE MUTATION; GENETIC RISK; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; BLOOD; BREAST TUMOR; GENETICS; MUTATION; PATHOLOGY; RISK; RISK FACTOR; TUMOR SUPPRESSOR GENE;

ADENOSINE TRIPHOSPHATE; ADULT; AGE FACTORS; BRCA2 PROTEIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; GENES, BRCA1; HETEROZYGOTE; HUMANS; MUTATION; NEOPLASM PROTEINS; ODDS RATIO; RISK FACTORS; TRANSCRIPTION FACTORS;

EID: 0031595195     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19981023)79:5<487::AID-IJC7>3.0.CO;2-X     Document Type: Article

References (20)

1. ABRAHAM, E.H., VOS, P., KAHN, J., GRUBMAN, S.A., JEFFERSON, D.M., DING, I. and OKUNIEFF, P., Cystic fibrosis hetero and homozygosity associated with inhibition of breast cancer growth. Nature (Med.), 2, 593-596 (1996).
2. BISHOP, T.D. and HOPPER, J.L., AT-tributable risks? Nature (Genet.), 15, 226 (1997).
3. CUMMINGS, M.C., WRIGHT, R.G., FURNIVAL, C.M., BAIN, C.J. and SISKIND, V., The feasibility of retrospective grading of breast cancer histology slides derived from multiple pathology services. Breast, 4, 179-182. (1995)
4. EISINGER, F., STOPPA-LYONNET, D., LONGY, M., KERANGUEVEN, F., NOGUCHI, T., BAILLY, C., VINCENT-SALMON, A., JACQUEMIER, J., BIRNBAUM, D. and SOBOL, H., Germ line mutations at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res., 56, 471-474 (1996)
5. ELSTON, C.W. and ELLIS, I.O., Pathological prognostic factors in breast cancer. Histopathology, 19, 403-410 (1991).
6. FRIERSON, H.F., WOLBER, R.A., BEREAN, K.W., FRANQUEMONT, D.W., GAFFEY, M.J., BOYD, J.C. and WILBUR, D.C., Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Amer. J. Clin. Pathol., 105, 195-199 (1995).
7. HOPPER, J.L., GILES, G.G., MCCREDIE, M.R.E. and BOYLE, P., Background, rationale and protocol for a case-control-family study of breast cancer. Breast, 3, 79-86 (1994).
8. KEREM, B-S., ROMMENS, J.M., BUCHANAN, J.A., MARKIEWICZ, D., COX, T.K., CHAKRAVARTI, A., BUCHWALD, M and TSUI, L-C., Identification of the cystic fibrosis gene: genetic analysis. Science, 245, 1073-1080 (1989).
9. LAKHANI, S.R., EASTON, D.F. STRATTON, M.R. and THE BREAST CANCER LINKAGE CONSORTIUM, Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet. 349, 1505-1510 (1997).
10. MARCUS, J.N., WATSON, P., PAGE, D.L., NAROD, S.A., LENOIR, G.A., TONIN, P., LINDER-STEVENSON, L., SALERNO, G., CONWAY, T.A. and LYNCH, H.T., Hereditary breast cancer-pathobiology, prognosis and BRCA1 and BRCA2 linkage. Cancer, 77, 697-709 (1996).
11. MCCREDIE, M.R.E., DITE, G., GILES, G.G. and HOPPER, J.L., Breast cancer in Australian women under the age of 40. Cancer Causes Control, (1998) Cancer Causes and Control 9, 189-198.
12. MEHTA, C.R., PATEL, N.R. and GREY, R., Computing an exact confidence interval for the common odds ratio in several 2×2 contingency tables. J. Amer. Stat. Assoc., 80, 969-973 (1985).
13. NEGLIA, J.P., FITZSIMMONS, M.P.H., MAISONNEUVE, P., SCHONI, M.H., SCHONI-AFFOLTER, F., COREY, M., LOWENFELS, A.B. and THE CYSTIC FIBROSIS AND CANCER STUDY GROUP, The risk of cancer among patients with cystic fibrosis. N. Engl. J. Med., 332, 494-499 (1995).
14. NEWMAN, B., BUTLER, L.M., MILLIKAN, R.C., MOORAN, P.G. and KING, M.-C., Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. J. amer. med. Ass., 279, 915-921 (1998).
15. RAPAPORT, E., FISHMAN, R.F. and GERCEL, C., Growth inhibition of human tumour cells in soft agar cultures by treatment with low levels of adenosine 5′-triphosphate. Cancer Res., 43, 4402-4406 (1983).
16. REISIN, I.L., PRAT, A.G., ABRAHAM, E.H., AMARA, J.F., GREGORY, R.J., AUSIELLO, D.A. and CANTIELLO, H.F., The cystic fibrosis transmembrane conductance regulator is a dual ATP and chloride channel. J. biol. Chem., 269, 20584-20591 (1994).
17. REMVIKOS, Y., MAGDELENAT, H., and DUTRILLAUX, B., Genetic evolution of breast cancers. III: Age-dependent variations in the correlations between biological indicators of prognosis. Breast Cancer Res. Treat., 34, 25-33 (1996).
18. SOUTHEY, M.C., BATTEN, L.E., MCCREDIE, M.M., GILES, G.G., DITE, G., HOPPER, J.L. and VENTER, D.J., Estrogen receptor polymorphism at codon 325 and risk of breast cancer before the age of 40. J. nat. Cancer Inst., (1998a) 90(7) 532-536.
19. SOUTHEY, M.C., TESORIERO, A.A., ANDERSEN, C.R., JENNING, K.M., BROWN, S.M., DITE, G.S., JENKINS, M.A., OSBORNE, R., MASKIELL, J.A., PORTER, L., GILES, G.G., MCCREDIE, M.R.E., HOPPER, J.L. and VENTER, D.J. BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer. British Journal of Cancer (in press). (1998b).
20. WARREN, N., HOLMES, J.A., AL-JADER, L., WEST, R.R., LEWIS, D.C. and PADUA, R.A., Frequency of carriers of cystic fibrosis gene among patients with myeloid malignancy and melanoma. Brit. Med. J., 302, 760-761 (1991).